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The effect of high glucose on lipid 
metabolism in the human placenta
Charlotte H. Hulme  1,2, Anna Nicolaou  3,4, Sharon A. Murphy4, Alexander E. P. Heazell  1,2, 
Jenny E. Myers1,2 & Melissa Westwood  1,2
Diabetes mellitus (DM) during pregnancy can result in fetal overgrowth, likely due to placental 
dysfunction, which has health consequences for the infant. Here we test our prediction from previous 
work using a placental cell line that high glucose concentrations affect placental lipid metabolism. 
Placentas from women with type 1 (n = 13), type 2 (n = 6) or gestational (n = 12) DM, BMI-matched to 
mothers without DM (n = 18), were analysed for lipase and fatty acid transport proteins and fatty acid 
and triglyceride content. Explants from uncomplicated pregnancies (n = 6) cultured in physiological or 
high glucose were similarly analysed. High glucose levels did not alter placental lipase or transporter 
expression or the profile and abundance of fatty acids, but triglyceride levels were higher (p < 0.05), 
suggesting reduced β- oxidation. DM did not affect placental protein expression or fatty acid profile. 
Triglyceride levels of placentas from mothers with pre-existing DM were similar to controls, but 
higher in obese women with gestational DM. Maternal hyperglycemia may not affect placental fatty 
acid uptake and transport. However, placental β-oxidation is affected by high glucose and reduced 
in a subset of women with DM. Abnormal placental lipid metabolism could contribute to increased 
maternal-fetal lipid transfer and excess fetal growth in some DM pregnancies.
Pregnancies complicated by diabetes mellitus (DM) are associated with adverse perinatal outcomes, most com-
monly relating to fetal overgrowth (macrosomia). Macrosomic infants can suffer from stillbirth, birth injuries and 
post-natal metabolic disturbances and are more likely to develop obesity, DM and cardiovascular disease in later 
life1. Maternal hyperglycemia is associated with fetal macrosomia2, yet the role of the placenta, the organ respon-
sible for transferring oxygen and nutrients from mother to fetus, in mediating this effect is not well understood. 
Our previous work using an unbiased systems biology approach to study a placental cell line (BeWo) response to 
high glucose levels highlighted aberrant trophoblast lipid metabolism and β-fatty acid oxidation3.
Maternal plasma free fatty acids are elevated in pregnancies complicated by DM4. It is thought that these fatty 
acids are transferred across the placenta to fetal adipose tissue where they are esterified into triglycerides using 
glycerol derived from excess maternal glucose, thereby contributing to macrosomia5. However, it is possible that 
maternal glucose may also affect placental lipid metabolism and the transfer of triglycerides from mother to fetus.
In order to enter the placenta, maternal circulating triglycerides carried in lipoproteins must be hydrolysed at 
the placental membrane by placental lipases (endothelial lipase (EL) or lipoprotein lipase (LPL))6,7. While some 
of the resulting free fatty acids can passively diffuse into the placental trophoblast cells, most require facilitated 
transport by membrane-bound and intracellular proteins6, such as fatty acid translocase (FAT) and fatty acid 
transporter family proteins (FATP1–6)6. Once inside the placenta, fatty acids can be directly transported into the 
fetal circulation, metabolised via β-oxidation8 or stored as triglycerides for subsequent transfer to the fetal circu-
lation. The rate-limiting step for β-oxidation is the conversion of fatty acyl CoA to acylcarnitine in a reaction that 
is catalysed by carnitine palmityltransferase (CPT1)8. This study assessed how high glucose levels affect fatty acid 
transport and metabolism by placental trophoblast and whether these are disrupted in placentas from women 
with type 1 and type 2 DM.
1School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester 
Academic Health Sciences Centre, Manchester, M13 9PT, UK. 2Maternal and Fetal Health Research Centre, St 
Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, 
Manchester, Manchester, M13 9WL, UK. 3Lydia Becker Institute of Immunology and Inflammation, The University 
of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, UK. 4School of Heath Sciences, 
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, 
Manchester, M13 9PT, UK. Correspondence and requests for materials should be addressed to M.W. (email: melissa.
westwood@manchester.ac.uk)
Received: 8 April 2019
Accepted: 4 September 2019
Published: xx xx xxxx
open
2Scientific RepoRtS |         (2019) 9:14114  | https://doi.org/10.1038/s41598-019-50626-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Results
Effect of high glucose levels on lipid metabolism in placental explants from uncomplicated 
pregnancies. Initially, we sought to confirm our prediction from previous work3 – that lipid metabolism is 
altered in a choriocarcinoma cell-line (BeWo) exposed to high (25 mM) glucose levels - by assessing the effect 
of such glucose concentrations on the triglyceride content of placental explants isolated from uncomplicated 
pregnancies at term (Table 1). The data presented in Fig. 1 show that glucose promotes placental triglyceride 
accumulation; levels were 2.7-fold greater (p < 0.05) in placental explants exposed to high glucose versus explants 
maintained at physiological glucose concentrations.
Next we investigated whether the glucose-mediated increase in placental triglyceride levels was a consequence 
of altered uptake or transport of fatty acids by determining if glucose affects the expression of EL, LPL, FATP2, 
FATP4 and FAT, key proteins required for these processes, and/or the level of individual fatty acids accumulated 
in the placenta9–12. Immunohistochemical analyses (shown in Fig. 2) revealed that trophoblast express both EL 
and LPL in abundance, while endothelium mainly expresses EL (Fig. 2A,B). FAT (Fig. 2C) FATP2 (Fig. 2D) and 
FATP4 (Fig. 2E) were expressed by all cellular compartments of the placenta, though FATP2 was the most abun-
dant. Treatment of placental explants with high glucose did not alter the localisation or intensity of staining for 
the lipases or FA transporters (Fig. 2A–E; p > 0.05).
Analysis of the total level of each fatty acid present in placental explants cultured in physiological concentra-
tion of glucose (5 mM) (Supplementary Table 1) showed that palmitic acid, stearic acid, oleic acid and arachidonic 
acid were present in greatest abundance. Neither the profile, nor relative abundance of the fatty acids present in 
placental explants were affected by exposing tissue to high levels of glucose (Supplementary Table 1; p > 0.05).
T1DM (n = 13) T2DM (n = 6)
GDM (BMI < 30) 
(n = 6)
GDM (BMI ≥ 30) 
(n = 6)
Control (BMI < 30) 
(n = 9)
Control (BMI ≥ 30) 
(n = 9) p
BMI (kg/m2) 25 (20–33) 33 (22–41) 26.1 (22–29) 37.9 (32–47) 22 (22–27) 31 (30–32) ns
Maternal Age (years) 32 (19–43) 38 (26–42) 33 (26–41) 35 (29–41) 34 (29–39) 33 (21–42) ns
Parity 1 (0–5) 2 (0–5) 1 (0–3) 4 (1–9) 1 (0–2) 1 (1–3) ns
Caucasian (%) 80 83 50 67 77 67 ns
Smoker (%) 0 0 0 0 0 0 ns
Gestation (week + days) 37 + 1 (36 + 1–39 + 0)
37 + 3 
(34 + 0–39 + 0)
38 + 4 
(36 + 0–40 + 4)
38 + 4 
(38 + 0–40 + 3)
39 + 0 
(36 + 5–41 + 4)
39 + 1 
(38 + 3–41 + 6) ns
Male (%) 40 83 50 33 33 55 ns
Caesarean (%) 87 50 50 83 77 73 ns
Birth Weight (g) 3400 (2660–4340) 3209 (2990–3867) 3338 (3035–3720) 4204 (3580–4518) 3080 (2580–3800) 3640 (3180–4200) ns
Birthweight centile§ 77.5 (43–100) 67.0 (35–95) 62.8 (30–89) 96.7 (94–100) 43 (12–80) 52 (30–88) a) <0.05
Large (>90th) for gestational 
age (%) 5/13 (42.8) 2/6 (33.3) 0/6 (0) 6/6 (100) 0/9 (0) 0/9 (0) b) <0.05
HbA1C (3rd trimester) 
(mmol/mmol) 49 (37–62) 46 (23–72)
Table 1. Demographic, obstetric and biophysical data for patient participants with type 1 diabetes (T1DM), 
type 2 diabetes (T2DM), gestational diabetes and a BMI ≤ 30 (GDM BMI ≤ 30), gestational diabetes and a 
BMI ≥ 30 (GDM BMI ≥ 30) and BMI matched controls. Data are median (range). Abbreviations: BMI, body 
mass index; §customised birthweight centile42 a) - T1 DM compared to controls with a BMI ≤ 30; Kruskal-Wallis 
test with Dunn’s post-hoc test; b) – Chi-square test.
Figure 1. Explants of placenta from uncomplicated pregnancies (n = 6) were cultured for 18 hours in medium 
containing either 5 mM or 25 mM D-glucose. Explant triglyceride content was measured, in duplicate, using 
a commercially available kit and concentrations, normalised to protein content, are presented as median and 
range. *p < 0.05; Mann-Whitney test.
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We therefore explored the possibility that altered placental fatty acid metabolism, specifically their reduced 
catabolism via β-oxidation, might provide an explanation for the glucose-induced increase in triglyceride levels. 
The observation that glucose-stimulated accumulation of triglyceride is attenuated in explants co-cultured with 
all doses of clofibrate (10–40 μM), a PPARα agonist that enhances the expression of CPT1, the rate limiting step 
for β-oxidation, provides indirect support for this hypothesis (Fig. 3).
Characterisation of fatty acid uptake and metabolism in placentas from pregnancies compli-
cated by pre-existing maternal DM. Our assessment of the expression of EL, LPL and fatty acid trans-
porters in placentas obtained from women with T1DM or T2DM (Table 1) suggested that both the location and 
level of each of these proteins are similar to that observed in placentas from BMI-matched uncomplicated preg-
nancies (p > 0.05; Fig. 4). Similarly, the profile and level of fatty acids found in placental tissue was not affected by 
the presence of maternal DM (Supplementary Table 2; p > 0.05; Kruskal-Wallis).
Surprisingly, analysis of the triglyceride content of explants from mothers with DM revealed that neither 
T1DM nor T2DM affected placental triglyceride accumulation when compared to their respective BMI-matched 
controls (Fig. 5). These data contrast with the observations made in explants exposed to high (25 mM) glucose 
levels ex vivo and therefore, as a control, we also assessed the level of triglycerides in placentas obtained from 
pregnancies complicated by gestational DM as a previous study reported elevated levels in such tissue13. We also 
found the level of triglycerides in placentas from mothers with gestational diabetes to be significantly higher but 
only in those with concurrent obesity (Fig. 5).
Discussion
Our previous systems biology analysis of a trophoblast cell line (BeWo) exposed to high glucose levels predicted 
alterations in placental lipid metabolism3 that could contribute to the enhanced fetal growth often observed in 
pregnancies complicated by maternal DM. Our current analysis of human placental explants suggests that pla-
cental lipid metabolism, but not uptake or transport, is affected by supraphysiological glucose levels; however, this 
aspect of placental function appears to be maintained in women who have received prolonged hypoglycaemic 
treatment during pregnancy.
Our immunohistochemical analysis of placental lipase expression revealed that both EL and LPL are expressed 
by trophoblast. These data suggest that, in contrast to previous hypotheses7, EL also has an important role to 
Figure 2. Immunohistochemical analysis of placental tissue from uncomplicated term pregnancies (maternal 
BMI < 30) cultured in 5 mM (circle) or 25 mM (square) D-glucose for (A) endothelial lipase, (B) lipoprotein 
lipase, (C) fatty acid translocase, (D) fatty acid transporter protein (FATP) 2 and (E) FATP4. T – trophoblast,  
E – endothelium, S - stroma, IVS – intervillous space. Images are representative of data obtained from 6 
different placentas. The intensity of staining in the trophoblast and endothelium of explants from each placenta 
was scored as low (0), medium (1) or high (2) from a mean of ten images; bar represents the median value of 6 
placentas. Data were compared using Wilcoxon matched-pairs analysis; no differences in staining for either of 
the lipases or the fatty acid transporters was observed following explant culture in 5 mM Vs 25 mM D-glucose 
(p > 0.05).
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play in the hydrolysis of maternal lipoproteins as the lysophospholipids generated by EL activity can be further 
hydrolysed (by EL) to provide a source of fatty acids for the placenta14; this suggestion is further supported by 
reports of an adequate supply of FA to the fetus in women with LPL deficiency15, and, importantly, unlike LPL, EL 
expression by trophoblast is maintained through to term11.
We found no evidence of altered lipase expression in placentas exposed, albeit for relatively short time periods, 
to high glucose ex vivo, though our data on in vivo exposure (from placentas from women with DM) support 
this finding. Our data on placental lipase expression corroborate previous reports relating to LPL expression in 
placentas from women with type 1 DM16,17, but others have found higher EL expression in placentas from such 
pregnancies, particularly in women with poor glycemic control16. Therefore, it is possible that satisfactory gly-
caemic control during pregnancy, which was evident amongst the women in our study, enables maintenance of 
appropriate EL expression.
The expression of fatty acid transporter proteins FAT, FATP2 and FATP4 in placentas from pregnancies 
complicated by DM has not been assessed previously, though others have demonstrated increased expression 
of FATP2 at the basal (fetal-facing) membrane in pregnancies complicated by obesity (defined in that study as 
BMI > 25)18. Our study did not corroborate this finding as the expression of FATP2 in the trophoblast of placentas 
from women with a BMI ≥ 30 was similar to that observed in tissue from women with a normal BMI, although we 
did not specifically quantify expression at the basal membrane. In fact, none of the fatty acid transporter proteins 
demonstrated differential abundance as a consequence of ex vivo high glucose or in vivo exposure. Although we 
acknowledge that a limitation of our study is that we did not assess whether the activity of the lipases and trans-
porter proteins, which also influences the availability of fatty acids for metabolism, is altered as a consequence of 
exposure to altered glucose conditions or maternal DM, our data on protein expression coupled with our finding 
that the profile and concentrations of fatty acids present in the placenta was unaffected by ex vivo exposure to high 
glucose, or by the presence of maternal DM, suggest that changes solely to the glucose environment are unlikely 
to alter fatty acid transport into and across the placenta. Rather, any such alterations are likely to be the conse-
quence of composite changes to the metabolic milieu19, including hyperinsulinaemia and the altered cytokine/
chemokine profile reflective of systemic inflammation20 in DM. Nonetheless, it may be beneficial to study the 
content of the syncytial microvillous (maternal-facing) and basal membranes separately as well as whole tissue 
homogenates, as others have reported altered levels of oleic acid and linoleic acid in the basal membrane of pla-
centas from other pregnancies complications, including fetal growth restriction21. However, our study identified 
palmitic acid, arachidonic acid, a long chain polyunsaturated fatty acid required for fetal neural development22, 
oleic acid and stearic acid to be the most abundant fatty acids in term placental tissue, which is in keeping with 
previous reports21.
Whilst exposure to aberrant glucose levels appears to have no effect on placental fatty acid uptake and/or 
transport, our data are indicative of an effect on β-oxidation, as reported by others13. Term placental explants 
cultured in high glucose conditions had higher levels of triglycerides, suggesting that under such conditions, 
cellular energy is provided by glycolysis rather than lipid oxidation, enabling fatty acid esterification for storage 
in the form of triglycerides23. This putative mechanism is supported by data showing that treatment with the 
PPARα agonist, clofibrate resulted in attenuation of the glucose-stimulated increase in placental triglyceride lev-
els. PPARα up-regulates CPT124, the rate-limiting enzyme for fatty acid β-oxidation by catalysing the conversion 
of fatty acyl CoA to acetylcarnitine. Similarly, Martinez et al., demonstrated reduced triglyceride levels in explants 
of placenta from control and diabetic rats following culture with clofibrate23. Interestingly, PPARα levels are 
reduced in placentas from streptozotocin-induced diabetic rats 25, however activation of the receptor using the 
specific ligand, leukotriene B4, led to a decrease in placental and fetal weight in such animals 25, suggesting that 
Figure 3. Placental explants from uncomplicated pregnancies (n = 9) were cultured overnight in 25 mM 
D-glucose and then switched to media containing 25 mM D-glucose in the absence (control) or presence 
of Clofibrate (10, 20 or 40 μM) for a further 18 hours. Explant triglyceride content was measured, (technical 
duplicates), using a commercially available colorimetric kit and concentrations were normalised to protein 
content. Data are presented as % change (median and range) relative to culture in 25 mM D-glucose alone 
(shown as line at 100%). ***p < 0.001 versus culture in 25 mM D-glucose alone; Wilcoxon-signed rank test.
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reducing the potential for glucose stimulated storage of fatty acids as triglycerides could reduce the availability 
of fatty acids for transfer to the fetus, thereby preventing excessive fetal growth. Nonetheless, further studies to 
directly assess the effect of PPARα on CPT1 expression in placenta, as well as the other mechanisms potentially 
involved in glucose-mediated regulation of CPT1 activity and β-oxidation, e.g., enhanced acetyl CoA carboxylase 
production of malonyl CoA, are required to confirm our observations.
Contrary to our initial hypothesis, we did not observe increased triglyceride levels in placental explants from 
women with either type 1 or type 2 DM. This finding was unexpected, as others have reported elevated levels 
of triglycerides in placentas from women with gestational DM13. We therefore assessed the triglyceride content 
of such placentas as a control for our assay and also found increased levels, though only in tissue from mothers 
who had GDM and were also obese (BMI > 30). It is possible that our findings in women with pre-existing DM 
reflect the fact that these women have intensive monitoring and glucose-lowering treatment throughout their 
Figure 4. Placental tissue from pregnancies complicated by T1DM (n = 6) or T2DM (n = 6) and uncomplicated 
term pregnancies (maternal BMI < 30 (n = 6) and >30 (n = 6)) were stained using antibodies that recognise  
(A) endothelial lipase, (B) lipoprotein lipase, (C) fatty acid translocase, (D) fatty acid transporter protein 
(FATP) 2 or (E) FATP4 then analysed by scoring the intensity of staining in the trophoblast and endothelium 
as low (0), medium (1) or high (2). Data points represent the mean score from ten images, with the median 
value plotted as a bar. Circle - T1DM; square - T2DM; triangle - control BMI < 30; inverted triangle - control 
BMI > 30. Data were compared using the Kruskal-Wallis test; no differences in staining for the lipases or fatty 
acid transporters were observed, in either compartment, between the subject groups (p > 0.05).
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pregnancy with the majority achieving at least satisfactory blood glucose control in the third trimester (only two 
were admitted and delivered before 37 weeks secondary to concerns regarding glyacemic control). It is also likely 
that in vivo, abnormal glucose metabolism is not the sole cause of aberrant lipid metabolism within the placenta 
and that maternal insulin levels and dyslipidaemia may also be an important determinant of placental fatty acid 
metabolism. Previous studies have suggested that the balance between lipogenesis and lipolysis in pregnancies 
complicated by diabetes may be affected by maternal insulin concentrations26,27. Consequently, it is possible that 
lipid metabolism and triglyceride storage within the placentas of pregnancies complicated by type 1 and 2 dia-
betes may change following prolonged exposure to an altered maternal metabolic environment associated with 
prolonged hypoglycaemic treatment (insulin ± metformin).
The increase in triglycerides in women with gestational DM who are also obese suggests that obesity is a 
potentially important confounding factor present in many women with DM. Critically, the mean BMI in women 
with gestational DM investigated by Visiedo et al.13 was 25.9 (n = 8) meaning any effect of obesity would not 
have been evident. In our study, the women with high BMI and GDM, who all had macrosomic babies, may have 
had longer (unrecognized) exposure to elevated glucose levels without pharmacological treatment, and/or they 
may represent a severe phenotype within the GDM population. Furthermore, we acknowledge that the glucose 
Figure 5. Placental tissue was collected from women with type 1 DM (T1 DM; n = 13), type 2 DM (T2 DM; 
n = 6), GDM (BMI < 30 (n = 6), BMI > 30 (n = 6)) and BMI matched controls (BMI < 30; n = 9) and (BMI ≥ 30; 
n = 9). Triglyceride content of each placental homogenate was measured using a commercially available kit and 
concentrations, normalised to protein content; bar – median. *p < 0.05 Vs control BMI > 30, Kruskal-Wallis 
with Dunn’s post-hoc test.
Primary Antibody Secondary Antibody
Species Target
Gene 
ID Supplier
Working 
Concentration Species Target Supplier Concentration
Mouse Lipoprotein Lipase LPL Millipore (#MABC674) 5 µg/ml Goat Mouse IgG DAKO 7.5 mg/ml
Mouse Fatty Acid Translocase FAT Santa Cruz (sc-21772)
43 1 µg/ml
Rabbit Endothelial Lipase EL Pierce (#PA1-16799) 5 µg/ml Swine Rabbit IgG DAKO 4.4 mg/ml
Rabbit Fatty Acid Transporter 4 FATP4 Santa Cruz (#sc-25670)
44 1 µg/ml
Goat Fatty Acid Transporter 2 FATP2
Santa Cruz (#sc-
161311)45 0.27 µg/ml Rabbit Goat IgG DAKO 3.9 mg/ml
Mouse Non-immune IgG Sigma
At same 
concentration 
as primary 
antibody of 
interest
Goat Mouse IgG DAKO 7.5 mg/ml
Rabbit Non-immune IgG Sigma
At same 
concentration 
as primary 
antibody of 
interest
Swine Rabbit IgG DAKO 4.4 mg/ml
Goat Non-immune IgG Sigma
At same 
concentration 
as primary 
antibody of 
interest
Rabbit Goat IgG DAKO 3.9 mg/ml
Table 2. Antibodies used in immunohistochemical analysis of explants of human placenta obtained at term.
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concentration used in our ex vivo studies, chosen to reflect previous similar studies13,28,29 and our initial work 
indicating aberrant lipid metabolism in response to exposure to high glucose concentrations3, is likely higher than 
levels typically observed in pregnant women. Further studies to elicit the concentration of glucose needed to drive 
placental fatty acid metabolism towards storage as triglycerides are required to determine the level of hypergly-
cemia likely to provoke this effect in women with DM. Future studies should also consider fetal sex as data from 
pigs30 and rabbits31 suggest that the transfer and storage of fatty acids is higher in female placentas.
In conclusion, we have confirmed that high glucose leads to increased placental triglyceride levels, indicating 
decreased placental β-oxidation in a subset of women with DM and obesity, which could lead to an increase in 
lipid transfer and potentially excessive fetal growth. The effect of high glucose on placental β-oxidation can be 
attenuated using the PPARα agonist clofibrate. It is possible that targeting CPT1 using PPARα agonists could 
provide a novel therapeutic intervention to prevent excess placental esterification of fatty acids to triglycerides 
and attenuate the increased fetal growth observed in pregnancies complicated by maternal DM.
Methods
Human placental tissue collection and culture. Human placentas were collected following delivery of 
a singleton infant between 37 to 42 weeks gestation (Table 1) with informed, written consent in accordance with 
Research Ethics Committee approval (08/H1010/55 + 5, Manchester UK). As women with type 2 DM are often 
obese and obesity is associated with altered placental structure and function32–35 and altered fetal growth36,37, 
placentas were obtained from two groups of women without DM – those with a BMI < 30 and women that were 
obese (BMI ≥ 30) – resulting in two groups of ‘control’ placentas. Placentas from two groups of women with 
GDM were also collected (BMI < 30 and ≥30). Women were diagnosed with GDM following an oral glucose tol-
erance test performed after 24 weeks gestation or following abnormal home blood glucose monitoring in women 
with a history of prior GDM (n = 3).
In order to obtain an overall assessment of placental function, a full thickness sample (≈1 cm3) was cut from 
the centre, middle and edge of each placenta (along a ‘line’, chosen at random, radiating from the centre) then 
the three samples were pooled, washed with sterile, cold phosphate buffered saline and processed for subsequent 
immunohistochemistry or lipid analyses or dissected into explants (as described previously38) for immediate 
culture.
Explants were cultured in 1:1 DMEM:F12, containing 10% FBS and physiological (5 mM) or high (25 mM) 
levels of D-glucose for 18 h then fixed for immunohistochemistry analysis or processed for triglyceride analysis. 
In some experiments, explants cultured in high (25 mM) D-glucose were incubated for a further 18 h in the 
absence or presence of the PPARα agonist (which can upregulate CPT1 expression24), Clofibrate (10–40 μM; 
Sigma Aldrich), then analysed for triglyceride content. Culture for 18 h was used as this time point had previously 
been used in similar studies to assess the effects of high glucose concentration on placental explants13.
Immunostaining. Immunohistochemical analysis was performed on 5 µm sections of formalin-fixed 
wax-embedded villous tissue from the three regions of the placenta (centre, middle and edge) using colorimetric 
detection as described39 and the primary antibodies detailed in Table 2. Ten random images per section were cap-
tured and staining in trophoblast and endothelium separately quantified using a semi-quantitative scale (0 – no 
staining; 1 – some staining and 2 – heavy staining) by two scorers blinded to sample identity. The mean score for 
each placenta was calculated and tissue from different treatment and patient groups were analysed by Wilcoxon 
matched-pairs and Kruskal-Wallis with Dunn’s post-hoc tests respectively. p < 0.05 was considered to represent 
a statistically significant difference. Representative images of data obtained when using non-immune mouse or 
rabbit IgG as a negative control are presented in Supplementary Fig. 1.
Analysis of placental fatty acid composition. The profile and relative abundance of individual fatty 
acids in placental lipid extracts was investigated using gas chromatography as described before40; briefly: 100 mg 
of tissue (made up of tissue from the centre, middle and edge of the placenta) was homogenised in ice-cold 
chloroform:methanol (2:1 v/v) containing the anti-oxidant butylated hydroxytoluene (BHT) (0.01%) using 
a blade homogeniser (Ystral; 3 × 15 s). The lipid extracts were trans-esterified using a BF3-methanol solution 
(14%) with C21:0 (Supelco) as internal standard. Fatty acid methyl esters (FAME) were analysed on an Agilent 
6850 GC-FID gas chromatograph (Agilent Technologies) with a BPX70 capillary column (0.25 μm film, 60 m 
× 0.25 mm; SGE Europe Ltd) using helium as the carrier gas and a flame ionization detector. Fatty acids were 
identified by comparison of retention times to those obtained by analysis of FAME standards (Sulpeco, UK). Data 
reported as relative percentage weight of total fatty acids.
The effect of glucose on the percentage weight of individual fatty acids was assessed using the Wilcoxon-signed 
rank test. Differences in the percentage weight of individual fatty acids in placental tissue from T1DM and T2DM 
compared to their BMI-matched controls were measured using a Kruskal-Wallis test with a Dunn’s post-hoc test. 
p < 0.05 was considered to be statistically significant.
Analysis of placental triglyceride concentration. Triglycerides were extracted by homogenising pla-
cental tissue (20 mg, containing tissue from the centre, middle and edge of the placenta) using an electronic blade 
homogeniser (LTF Labortechnick, Germany) in HPLC- grade acetone then rotating samples overnight at 4 °C and 
centrifuging at 15,000 × g for 15 min. Triglyceride concentrations were measured using a commercial colorimet-
ric assay based upon enzymatic hydrolysis of the triglycerides by lipase to produce glycerol and free fatty acids, 
following manufacturers’ instructions (Caymann Chemical, Cambridge) and are presented as per mg of protein 
(determined using the Lowry method41). The effect of ex vivo glucose exposure on placental triglyceride content 
was assessed using a Mann-Whitney test whereas the Wilcoxon-signed rank test was used to analyse experiments 
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including clofibrate and the levels of triglyceride in placentas from the different patient groups were compared by 
Kruskal-Wallis. p < 0.05 was considered to represent a significant difference.
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